Alpha 2.0
Login Register
» Authors » Isabel Sanchez-Ortega

Isabel Sanchez-Ortega

Explore the profile of Isabel Sanchez-Ortega including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 540
Followers 0
Related Specialties
General Surgery
Hematology
Oncology
Top 10 Co-Authors
Anna Sureda
Rafael F Duarte
John A Snowden
Ibrahim Yakoub-Agha
Raffaella Greco
Francesco Onida
Montserrat Arnan
Annalisa Ruggeri
Rocio Parody
Christelle Ferra
Published In
Bone Marrow Transplant
Clin Infect Dis
Transplant Cell Ther
Blood
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
1.
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
Passweg J, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al.
Bone Marrow Transplant . 2025 Feb; PMID: 39939433
In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were...
2.
Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies
Chabannon C, Ruggeri A, Montoto S, van Biezen A, van der Werf S, Markslag A, et al.
Best Pract Res Clin Haematol . 2024 Aug; 37(2):101557. PMID: 39098799
The European society for Blood and Marrow Transplantation (EBMT) has a long-standing interest in the evaluation of hematopoietic cell transplantation. More than three decades ago, its members established a continental...
3.
Pitfalls in definitions on respiratory viruses and particularities of Adenovirus infection in hematopoietic cell transplantation patients: Recommendations from the EBMT practice harmonization and guidelines committee
Pinana J, Cesaro S, Mikulska M, Verweij P, Bergeron A, Neofytos D, et al.
Curr Res Transl Med . 2024 Jul; 72(3):103461. PMID: 39032263
In 2023, the EBMT Practice harmonization and Guidelines Committee partnered with the EBMT Infection Diseases Working Party (IDWP) to undertake the task of delivering best practice recommendations, aiming to harmonize...
4.
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, et al.
Bone Marrow Transplant . 2024 Jun; 59(9):1335. PMID: 38907026
No abstract available.
5.
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT
Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, et al.
Lancet Haematol . 2024 May; 11(6):e448-e458. PMID: 38796194
Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of this...
6.
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, et al.
Blood . 2024 Mar; 143(22):2227-2244. PMID: 38493484
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity...
7.
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
McLornan D, Czerw T, Damaj G, Ethell M, Gurnari C, Hernandez-Boluda J, et al.
Leukemia . 2024 Mar; 38(4):699-711. PMID: 38472477
Systemic Mastocytosis (SM) is a multifaceted clinically heterogeneous disease. Advanced SM (AdvSM) comprises three entities: aggressive SM (ASM), mast cell leukaemia (MCL) and SM with an associated hematologic neoplasm (SM-AHN),...
8.
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, et al.
Bone Marrow Transplant . 2024 Mar; 59(6):832-837. PMID: 38443706
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to...
9.
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)
Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, et al.
Cytotherapy . 2024 Feb; 26(7):681-685. PMID: 38416085
Cell and gene therapy poses evolving challenges. The current article summarizes the discussions held by European Regional Committee of the International Society for Cell & Gene Therapy and the European...
10.
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
Greco R, Alexander T, Papa N, Muller F, Saccardi R, Sanchez-Guijo F, et al.
EClinicalMedicine . 2024 Feb; 69:102476. PMID: 38361991
Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require...